VIR Stock Chart & Stats
$177.11
-$12.00(-7.59%)
At close: 4:00 PM EDT
$177.11
-$12.00(-7.59%)
Day’s Range― - ―
52-Week Range$138.61 - $225.59
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$36.58B
Enterprise Value$1.28B
Total Cash (Recent Filing)$528.59M
Total Debt (Recent Filing)$93.27M
Price to Earnings (P/E)―
Beta-0.15
Next Earnings
Nov 04, 2026EPS Estimate
-13.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.85
Shares Outstanding169,215,960
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.09
Price to Sales (P/S)12.18
P/FCF Ratio-2.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$397.69Price Target Upside124.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-33.16
Revenue Forecast (FY)$4.59B
Bulls Say, Bears Say
Bulls Say
Cash Runway And Balance SheetA roughly $1.01 billion liquidity position and projected runway into the second half of 2028 give Vir meaningful capacity to fund clinical programs without immediate financing pressure. This supports continued execution across hepatitis and oncology while providing flexibility through upcoming readouts.
Durable Hepatitis Clinical EfficacyThe Week 96 SOLSTICE results show sustained viral clearance and a substantial benefit for combination therapy over monotherapy. Durable efficacy, alongside strong biomarker results, can strengthen differentiation and support future regulatory, partnering, and commercialization efforts.
Strategic Oncology AllianceThe Gilead alliance validates Vir's PRO-XTEN technology and adds a well-resourced partner for later-stage development, manufacturing, and commercialization. Upfront funding, potential milestones, royalties, and equity support the platform while reducing the burden of advancing every asset independently.
Bears Say
Persistent Cash Burn And LossesSustained negative operating and free cash flow means Vir continues consuming liquidity to fund operations despite its strong balance sheet. If losses persist, the company may eventually need additional capital or reduce investment, limiting flexibility across its expanding clinical pipeline.
Dependence On Collaboration RevenueNear-term profitability depends heavily on upfront and milestone recognition from collaborations, which can be uneven and nonrecurring. This makes reported earnings less reflective of an established commercial engine and leaves financial performance exposed to deal timing and development outcomes.
Limited HDV Diagnosis And Uptake RiskLow current diagnosis rates could slow adoption of Vir's hepatitis delta therapies even if clinical and regulatory milestones are achieved. Expanding awareness and reflex testing will be important, but the pace of market development remains uncertain and could delay commercial revenue growth.
Vir Biotechnology News
VIR FAQ
What was Vir Biotechnology’s price range in the past 12 months?
Vir Biotechnology lowest stock price was $138.61 and its highest was $225.59 in the past 12 months.
What is Vir Biotechnology’s market cap?
Vir Biotechnology’s market cap is $36.58B.
When is Vir Biotechnology’s upcoming earnings report date?
Vir Biotechnology’s upcoming earnings report date is Nov 04, 2026 which is in 6 days.
How were Vir Biotechnology’s earnings last quarter?
Vir Biotechnology released its earnings results on Aug 05, 2026. The company reported $8.781 earnings per share for the quarter, beating the consensus estimate of $6.222 by $2.56.
Is Vir Biotechnology overvalued?
According to Wall Street analysts Vir Biotechnology’s price is currently Undervalued.
Does Vir Biotechnology pay dividends?
Vir Biotechnology does not currently pay dividends.
What is Vir Biotechnology’s EPS estimate?
Vir Biotechnology’s EPS estimate is -13.81.
How many shares outstanding does Vir Biotechnology have?
Vir Biotechnology has 169,215,960 shares outstanding.
What happened to Vir Biotechnology’s price movement after its last earnings report?
Vir Biotechnology reported an EPS of $8.781 in its last earnings report, beating expectations of $6.222. Following the earnings report the stock price went down -5.134%.
Which hedge fund is a major shareholder of Vir Biotechnology?
Currently, no hedge funds are holding shares in MX:VIR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vir Biotechnology Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$397.69 (124.55% Upside)
$397.69 (124.55% Upside)
Blogger Sentiment
Bullish
MX:VIR Sentiment 80%
Sector Average 65%
Sector Average 65%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
86.91%
12-Months-Change
Fundamentals
Return on Equity
-29.99%
Trailing 12-Months
Asset Growth
1.87%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Vir Biotechnology
Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases. Its pipeline features several key candidates: Sotrovimab (branded as Xevudy, or VIR-7832), a neutralizing monoclonal antibody for both treating and preventing SARS-CoV-2 infection; VIR-2218 and VIR-3434, aimed at hepatitis B virus; VIR-2482, targeting the prevention of influenza A virus; and VIR-1111, designed to prevent human immunodeficiency virus. The firm maintains a robust network of strategic partnerships and collaborations. These include grant support from organizations like the Bill & Melinda Gates Foundation and the National Institutes of Health. It holds option and licensing arrangements with entities such as Brii Biosciences Limited, and a collaboration and license agreement with Alnylam Pharmaceuticals, Inc. Further licensing relationships exist with The Rockefeller University and MedImmune, Inc. Collaborations extend to WuXi Biologics and Glaxo Wellcome UK Ltd., alongside a research agreement with GlaxoSmithKline Biologicals SA. Furthermore, Vir has secured a manufacturing contract with Samsung Biologics Co.,Ltd. for SARS-CoV-2 antibodies and a clinical development partnership with Gilead Sciences, Inc. focused on chronic hepatitis B virus. The company, established in 2016, is headquartered in San Francisco, California.
VIR Company Deck
VIR Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call conveyed strong clinical and commercial progress (notably robust SOLSTICE Week 96 efficacy, completion of registrational enrollment for ECLIPSE, manufacturing milestones for drug substance, a strengthened balance sheet with ~ $1.01B cash and substantive Astellas funding, and accelerated oncology development with VIR-5500 expansion cohorts). Offsetting risks include higher R&D and SG&A driven by milestone and one-time items, reliance on collaboration revenue for near-term profitability, low current HDV diagnosis rates that could limit short-term market uptake, remaining CMC/drug product activities, and ongoing C-suite hiring. On balance, the positives (clinical data, enrollment completion, cash runway, strategic partnerships and oncology momentum) materially outweigh the near-term operational and market risks.View all MX:VIR earnings summariesVIR Stock 12 Month Forecast
Average Price Target
$397.69
▲(124.55% Upside)